Results 121 to 130 of about 11,226 (207)
Biological Drivers of IMiD‐Induced Peripheral Neuropathy in Multiple Myeloma
eJHaem, Volume 7, Issue 3, June 2026.ABSTRACT The introduction of immunomodulatory drugs (IMiDs), such as thalidomide, lenalidomide and pomalidomide, have led to significant improvements in multiple myeloma (MM) treatment. Many patients now live 10 years or longer with their disease, making treatment‐related side effects increasingly important.
Sina A. Beer +2 more
wiley +1 more source
eJHaem, Volume 7, Issue 3, June 2026.ABSTRACT Background Multiple myeloma (MM) carries a high venous thromboembolism (VTE) risk; aspirin shows limited efficacy, while factor‐Xa inhibitors show promise. Objectives Evaluate apixaban for primary thromboprophylaxis in newly diagnosed MM (NDMM).
K. Alexandra Sanchez +5 more
wiley +1 more source
DaraEx verhindert Daratumumab-Interferenz im indirekten Antihumanglobulintest
, 2017 ZusammenfassungDaratumumab ist ein humaner, monoklonaler Anti-CD38-Antikörper, der zur Therapie des multiplen Myeloms eingesetzt wird. CD38 ist ein Oberflächenmolekül, das auf einer Reihe von Zellen und Geweben exprimiert wird, auch auf Erythrozyten ...
Hans-Gert Heuft +2 more
core +1 more source
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Advanced ScienceFirst‐line treatment of multiple myeloma, a prevalent blood cancer lacking a cure, using anti‐CD38 daratumumab antibody and lenalidomide is often inadequate due to relapse and severe side effects.
Yueh‐Hsiang Yu +11 more
doaj +1 more source
BCMA CAR T for AL Amyloidosis After Plasmacytic Relapse of Lymphoplasmacytic Lymphoma
eJHaem, Volume 7, Issue 3, June 2026.ABSTRACT Introduction Lambda immunoglobulin light chain (AL) amyloidosis associated with non‐IgM lymphoplasmacytic lymphoma (LPL) is rare and often refractory to conventional therapies. Treatment options for relapsed disease remain limited. Methods Here we describe the case of a patient with a history of LPL‐associated AL amyloidosis who had previously
Nadia Al Haddad +5 more
wiley +1 more source
Therapeutic Options for IgA Pemphigus in Patients Refractory to Dapsone
JEADV Clinical Practice, Volume 5, Issue 2, Page 415-424, June 2026.ABSTRACT IgA pemphigus is a rare autoimmune blistering disorder with limited therapeutic guidance available due to its rarity and complex presentation. This comprehensive analysis evaluates the therapeutic outcomes of 67 published patients, emphasising the significant role of dapsone as the first‐line treatment.
Lorenz Frasheri +2 more
wiley +1 more source
Liver International Communications, Volume 7, Issue 2, June 2026.ABSTRACT Monoclonal immunoglobulin deposition disease (MIDD) is a plasma cell disorder where immunoglobulin light‐ and/or heavy‐chains accumulate in various organs. Hepatic involvement can be challenging to diagnose, as manifestations are protean and Congo red staining is negative.
Bella L. Liu +5 more
wiley +1 more source
Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay
, 2019 Daratumumab, a monoclonal antibody used to treat relapsed or refractory multiple myeloma, can interfere with protein electrophoresis and immunofixation assays.
Ramanathan, Lakshmi V +4 more
core +1 more source
Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier +7 more
wiley +1 more source
, 2022 多発性骨髄腫 （multiple myeloma : MM） に対する抗ヒト CD38 抗体であるdaratumumab（DARA） 投与中の患者検体では，間接抗グロブリン試験 （indirect antiglobulin test : IAT） が偽陽性となる可能性がある。今回，dithiothreitol （DTT） を使用しない，DARA の干渉を回避する新たな検出法を開発することを目的として検討を行った。 DARA と赤血球の結合を評価するために，各濃度のDARA 存在下で CD38 の発現を
中尾, 沙希 +6 more
core